Dataset from A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00009367
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine if the addition of daratumumab to velcade
(bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared
with VMP alone in participants with previously untreated multiple myeloma who are ineligible
for high dose chemotherapy and autologous stem cell transplant (ASCT).
创建时间：
2026-04-09
